JP2005517925A - 分析装置及び方法 - Google Patents
分析装置及び方法 Download PDFInfo
- Publication number
- JP2005517925A JP2005517925A JP2003568389A JP2003568389A JP2005517925A JP 2005517925 A JP2005517925 A JP 2005517925A JP 2003568389 A JP2003568389 A JP 2003568389A JP 2003568389 A JP2003568389 A JP 2003568389A JP 2005517925 A JP2005517925 A JP 2005517925A
- Authority
- JP
- Japan
- Prior art keywords
- sample
- spectrum
- radiation
- thz
- resulting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 51
- 238000001228 spectrum Methods 0.000 claims abstract description 74
- 230000005855 radiation Effects 0.000 claims abstract description 61
- 230000001678 irradiating effect Effects 0.000 claims abstract description 6
- 230000009878 intermolecular interaction Effects 0.000 claims abstract description 4
- -1 polyethylene Polymers 0.000 claims description 23
- 239000000463 material Substances 0.000 claims description 18
- 239000004698 Polyethylene Substances 0.000 claims description 14
- 229920000573 polyethylene Polymers 0.000 claims description 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 229920003023 plastic Polymers 0.000 claims description 2
- 239000004033 plastic Substances 0.000 claims description 2
- 238000003908 quality control method Methods 0.000 claims 1
- 229920002521 macromolecule Polymers 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 96
- 238000010521 absorption reaction Methods 0.000 description 25
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 14
- 239000008103 glucose Substances 0.000 description 14
- 239000003814 drug Substances 0.000 description 13
- GGWBHVILAJZWKJ-KJEVSKRMSA-N ranitidine hydrochloride Chemical compound [H+].[Cl-].[O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 GGWBHVILAJZWKJ-KJEVSKRMSA-N 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 229960001520 ranitidine hydrochloride Drugs 0.000 description 11
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 239000012071 phase Substances 0.000 description 10
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- VMXUWOKSQNHOCA-UHFFFAOYSA-N N1'-[2-[[5-[(dimethylamino)methyl]-2-furanyl]methylthio]ethyl]-N1-methyl-2-nitroethene-1,1-diamine Chemical compound [O-][N+](=O)C=C(NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-UHFFFAOYSA-N 0.000 description 6
- 230000005540 biological transmission Effects 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 229940108322 zantac Drugs 0.000 description 6
- 229930091371 Fructose Natural products 0.000 description 5
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 5
- 239000005715 Fructose Substances 0.000 description 5
- 229910001218 Gallium arsenide Inorganic materials 0.000 description 5
- 239000004471 Glycine Substances 0.000 description 5
- 238000000862 absorption spectrum Methods 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 229960005489 paracetamol Drugs 0.000 description 4
- 229910052594 sapphire Inorganic materials 0.000 description 4
- 239000010980 sapphire Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 3
- 238000001069 Raman spectroscopy Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 229940127557 pharmaceutical product Drugs 0.000 description 3
- 229960000620 ranitidine Drugs 0.000 description 3
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 239000013074 reference sample Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 229910017119 AlPO Inorganic materials 0.000 description 2
- 229910005543 GaSe Inorganic materials 0.000 description 2
- 229910013641 LiNbO 3 Inorganic materials 0.000 description 2
- MITFXPHMIHQXPI-UHFFFAOYSA-N Oraflex Chemical compound N=1C2=CC(C(C(O)=O)C)=CC=C2OC=1C1=CC=C(Cl)C=C1 MITFXPHMIHQXPI-UHFFFAOYSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 229910007709 ZnTe Inorganic materials 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229910052785 arsenic Inorganic materials 0.000 description 2
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 2
- UHYPYGJEEGLRJD-UHFFFAOYSA-N cadmium(2+);selenium(2-) Chemical compound [Se-2].[Cd+2] UHYPYGJEEGLRJD-UHFFFAOYSA-N 0.000 description 2
- 229960000623 carbamazepine Drugs 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- HVFLCNVBZFFHBT-ZKDACBOMSA-N cefepime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 HVFLCNVBZFFHBT-ZKDACBOMSA-N 0.000 description 2
- 229960002100 cefepime Drugs 0.000 description 2
- 238000004042 decolorization Methods 0.000 description 2
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Substances CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 229910002804 graphite Inorganic materials 0.000 description 2
- 239000010439 graphite Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- UHKHUAHIAZQAED-UHFFFAOYSA-N phthalocyaninatoiron Chemical compound [Fe].N=1C2=NC(C3=CC=CC=C33)=NC3=NC(C3=CC=CC=C33)=NC3=NC(C3=CC=CC=C33)=NC3=NC=1C1=CC=CC=C12 UHKHUAHIAZQAED-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000010453 quartz Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- SBIBMFFZSBJNJF-UHFFFAOYSA-N selenium;zinc Chemical compound [Se]=[Zn] SBIBMFFZSBJNJF-UHFFFAOYSA-N 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229910052714 tellurium Inorganic materials 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- SYOPRZWROBOKGX-ZJSXRUAMSA-N 2-(3,4-dichlorophenyl)-n-[(1r,2r)-5-methoxy-2-pyrrolidin-1-yl-1,2,3,4-tetrahydronaphthalen-1-yl]-n-methylacetamide Chemical compound N1([C@H]2[C@@H](C=3C=CC=C(C=3CC2)OC)N(C)C(=O)CC=2C=C(Cl)C(Cl)=CC=2)CCCC1 SYOPRZWROBOKGX-ZJSXRUAMSA-N 0.000 description 1
- JELDFLOBXROBFH-UHFFFAOYSA-N 2-[[4-[[2-(2h-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl]quinoline Chemical compound C=1C=C2C=CC=CC2=NC=1COC(C=C1)=CC=C1OCC1=CC=CC=C1CC=1N=NNN=1 JELDFLOBXROBFH-UHFFFAOYSA-N 0.000 description 1
- PJKVJJYMWOCLIJ-UHFFFAOYSA-N 2-amino-6-methyl-5-pyridin-4-ylsulfanyl-1h-quinazolin-4-one;hydron;dichloride Chemical compound Cl.Cl.CC1=CC=C2NC(N)=NC(=O)C2=C1SC1=CC=NC=C1 PJKVJJYMWOCLIJ-UHFFFAOYSA-N 0.000 description 1
- JFPJVTNYCURRAB-UHFFFAOYSA-N 2-nitro-n-phenylacetamide Chemical compound [O-][N+](=O)CC(=O)NC1=CC=CC=C1 JFPJVTNYCURRAB-UHFFFAOYSA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- NPXUFPFFHANGDL-UHFFFAOYSA-N 5-methyl-2-(2-nitroanilino)thiophene-3-carbonitrile Chemical compound S1C(C)=CC(C#N)=C1NC1=CC=CC=C1[N+]([O-])=O NPXUFPFFHANGDL-UHFFFAOYSA-N 0.000 description 1
- ZVVCSBSDFGYRCB-UHFFFAOYSA-N 7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-8-propyl-3,4-dihydro-2h-chromene-2-carboxylic acid Chemical compound C1=CC(C(C)=O)=C(OC)C(CCC)=C1OCCCOC1=CC=C(CCC(O2)C(O)=O)C2=C1CCC ZVVCSBSDFGYRCB-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000005912 Lufenuron Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- HUMXXHTVHHLNRO-KAJVQRHHSA-N Prednisolone tebutate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)CC(C)(C)C)(O)[C@@]1(C)C[C@@H]2O HUMXXHTVHHLNRO-KAJVQRHHSA-N 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
- XEEQGYMUWCZPDN-UHFFFAOYSA-N [2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol Chemical compound C=1C(C(F)(F)F)=NC2=C(C(F)(F)F)C=CC=C2C=1C(O)C1CCCCN1 XEEQGYMUWCZPDN-UHFFFAOYSA-N 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 229960003473 androstanolone Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960005430 benoxaprofen Drugs 0.000 description 1
- UPTJXAHTRRBMJE-UHFFFAOYSA-N benzo[b][1]benzazepine-11-carboxamide;dihydrate Chemical compound O.O.C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 UPTJXAHTRRBMJE-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960005361 cefaclor Drugs 0.000 description 1
- 229960001761 chlorpropamide Drugs 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- HJKBJIYDJLVSAO-UHFFFAOYSA-L clodronic acid disodium salt Chemical compound [Na+].[Na+].OP([O-])(=O)C(Cl)(Cl)P(O)([O-])=O HJKBJIYDJLVSAO-UHFFFAOYSA-L 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 229960003290 cortisone acetate Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 238000000351 diffuse reflectance infrared Fourier transform spectroscopy Methods 0.000 description 1
- WLOHNSSYAXHWNR-NXPDYKKBSA-N dirithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H]2O[C@H](COCCOC)N[C@H]([C@@H]2C)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 WLOHNSSYAXHWNR-NXPDYKKBSA-N 0.000 description 1
- 229960004100 dirithromycin Drugs 0.000 description 1
- FXHKSTYWSZZOBF-NTEVMMBTSA-L disodium;(3s)-4-[2-[1-(4-fluorophenyl)-3-propan-2-ylindol-2-yl]ethynyl-oxidophosphoryl]-3-hydroxybutanoate Chemical compound [Na+].[Na+].C12=CC=CC=C2C(C(C)C)=C(C#CP([O-])(=O)C[C@@H](O)CC([O-])=O)N1C1=CC=C(F)C=C1 FXHKSTYWSZZOBF-NTEVMMBTSA-L 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960001880 fosinopril sodium Drugs 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 230000008863 intramolecular interaction Effects 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 238000012886 linear function Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- PWPJGUXAGUPAHP-UHFFFAOYSA-N lufenuron Chemical compound C1=C(Cl)C(OC(F)(F)C(C(F)(F)F)F)=CC(Cl)=C1NC(=O)NC(=O)C1=C(F)C=CC=C1F PWPJGUXAGUPAHP-UHFFFAOYSA-N 0.000 description 1
- 229960000521 lufenuron Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 229960005285 mofebutazone Drugs 0.000 description 1
- REOJLIXKJWXUGB-UHFFFAOYSA-N mofebutazone Chemical compound O=C1C(CCCC)C(=O)NN1C1=CC=CC=C1 REOJLIXKJWXUGB-UHFFFAOYSA-N 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- FBFBRAFXKGRRHI-UHFFFAOYSA-N n-(4-aminophenyl)sulfonyl-4-propan-2-yloxybenzamide Chemical compound C1=CC(OC(C)C)=CC=C1C(=O)NS(=O)(=O)C1=CC=C(N)C=C1 FBFBRAFXKGRRHI-UHFFFAOYSA-N 0.000 description 1
- LQZGUJSFLJIJKA-UHFFFAOYSA-N n-(4-methyl-2-nitrophenyl)acetamide Chemical compound CC(=O)NC1=CC=C(C)C=C1[N+]([O-])=O LQZGUJSFLJIJKA-UHFFFAOYSA-N 0.000 description 1
- RQTOOFIXOKYGAN-UHFFFAOYSA-N nedocromil Chemical compound CCN1C(C(O)=O)=CC(=O)C2=C1C(CCC)=C1OC(C(O)=O)=CC(=O)C1=C2 RQTOOFIXOKYGAN-UHFFFAOYSA-N 0.000 description 1
- 229960004398 nedocromil Drugs 0.000 description 1
- 229960001783 nicardipine Drugs 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229960000649 oxyphenbutazone Drugs 0.000 description 1
- HFHZKZSRXITVMK-UHFFFAOYSA-N oxyphenbutazone Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 HFHZKZSRXITVMK-UHFFFAOYSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical compound N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 description 1
- OUNSOXPSCMCFHX-UHFFFAOYSA-N pinadoline Chemical compound ClCCCCC(=O)NNC(=O)N1CC2=CC=CC=C2OC2=CC=C(Cl)C=C12 OUNSOXPSCMCFHX-UHFFFAOYSA-N 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960004259 prednisolone tebutate Drugs 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 229910052968 proustite Inorganic materials 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- TVTJZMHAIQQZTL-WATAJHSMSA-M sodium;(2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylate Chemical compound [Na+].C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C([O-])=O)CCCC1=CC=CC=C1 TVTJZMHAIQQZTL-WATAJHSMSA-M 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000012306 spectroscopic technique Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 229960005404 sulfamethoxazole Drugs 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N22/00—Investigating or analysing materials by the use of microwaves or radio waves, i.e. electromagnetic waves with a wavelength of one millimetre or more
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
- G01N21/35—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light
- G01N21/3563—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light for analysing solids; Preparation of samples therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
- G01N21/35—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light
- G01N21/3581—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light using far infrared light; using Terahertz radiation
Landscapes
- Physics & Mathematics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Electromagnetism (AREA)
- Toxicology (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
- Investigating Or Analyzing Materials By The Use Of Ultrasonic Waves (AREA)
Abstract
Description
25GHzから20THzまでの範囲における複数の周波数を有する放射を試料に照射するためのエミッター、
試料から反射される及び/又は試料によって透過させられる放射を検出すると共に試料のスペクトルを生成させるための検出器、
分子間の振動から発生するスペクトルにおける構造を識別するための手段
を含む。
Claims (21)
- 試料のマクロ構造を調査する方法であって、
当該方法は、
25GHzから20THzまでの範囲における複数の周波数を有する放射を前記試料に照射すること、
前記試料から反射された及び/又は前記試料によって透過させられた放射を検出して、前記試料のスペクトルを得ること、並びに
分子間相互作用から発生する結果として生じるスペクトルにおける構造を識別すること
を含む方法。 - 25THzから120THzまでの範囲における放射を前記試料に照射すること、及び分子内の振動から発生する結果として生じるスペクトルにおける構造を識別することをさらに含む請求項1に記載の方法。
- 前記放射は、パルス化された放射である請求項1又は2に記載の方法。
- 前記放射は、連続波の放射である請求項1又は2に記載の方法。
- 前記試料の屈折率を導出する段階をさらに含む請求項1乃至4のいずれか一項に記載の方法。
- 前記試料は、照射の間に150Kまでの最大の温度で保持される請求項1乃至5のいずれか一項に記載の方法。
- 前記試料は、10Kまでの最大の温度に保持される請求項6に記載の方法。
- 前記試料は、照射されるとき真空下にある請求項1乃至7のいずれか一項に記載の方法。
- 前記試料は、照射されるとき乾燥した窒素又は乾燥した空気の下にある請求項1乃至7のいずれか一項に記載の方法。
- 前記試料は、粉末化されると共に照射より先に不活性な材料と混合される請求項1乃至9のいずれか一項に記載の方法。
- 前記不活性な材料は、ポリエチレンである請求項10に記載の方法。
- 前記試料は、最大限でも5mmの厚さである請求項1乃至11のいずれか一項に記載の方法。
- 前記結果として生じるスペクトルは、分子の既知のスペクトルと比較される、品質の制御に適合した、請求項1乃至12のいずれか一項に記載の方法。
- 前記結果として生じるスペクトルは、分子の既知のスペクトルと比較される、貯蔵の後に試料を評価することに適合した、請求項1乃至13のいずれか一項に記載の方法。
- 前記試料は、プラスチックの袋に位置させられる間に、照射される請求項1乃至14のいずれか一項に記載の方法。
- 前記結果として生じるスペクトルにおける構造を識別する段階は、前記結果として生じるスペクトルを既知のスペクトルと比較することを含む請求項1乃至15のいずれか一項に記載の方法。
- 分子の試料のマクロ構造を研究する装置であって、
当該装置は、
25GHzから20THzまでの範囲における複数の周波数を有する放射を前記試料に照射するエミッター、
前記試料から反射された及び/又は前記試料によって透過させられた放射を検出すると共に前記試料のスペクトルを生成させる検出器、
分子間相互作用から発生するスペクトルにおける構造を識別する手段
を含む装置。 - 前記構造を識別する手段は、検出されたスペクトルを既知のスペクトルと比較するための手段を含む請求項17に記載の装置。
- 当該装置は、所望の多形相の既知のスペクトルを設定する手段及び前記既知のスペクトルと前記試料の各々から生成させられたスペクトルを比較する手段を含む、一群の試料の質を監視するように構成された、請求項18に記載の装置。
- 添付する図面のいずれか一つを参照して実質的に請求の範囲又は明細書に記載された方法。
- 添付する図面のいずれか一つを参照して実質的に請求の範囲又は明細書に記載された装置。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0203698A GB2385415B (en) | 2002-02-15 | 2002-02-15 | An analysis apparatus and method |
PCT/GB2003/000660 WO2003069318A2 (en) | 2002-02-15 | 2003-02-14 | An analysis apparatus and method |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2005517925A true JP2005517925A (ja) | 2005-06-16 |
Family
ID=9931206
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003568389A Pending JP2005517925A (ja) | 2002-02-15 | 2003-02-14 | 分析装置及び方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US7244934B2 (ja) |
EP (1) | EP1474675A2 (ja) |
JP (1) | JP2005517925A (ja) |
AU (1) | AU2003207316A1 (ja) |
GB (1) | GB2385415B (ja) |
WO (1) | WO2003069318A2 (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008083020A (ja) * | 2006-03-17 | 2008-04-10 | Institute Of Physical & Chemical Research | 分析方法及び分析装置 |
WO2008129959A1 (ja) * | 2007-04-13 | 2008-10-30 | Arkray, Inc. | 分光測定用ペレット、このペレットの製造方法及びこのペレットを用いた分光測定方法 |
JP2010249564A (ja) * | 2009-04-13 | 2010-11-04 | Nippon Telegr & Teleph Corp <Ntt> | 溶解性分光測定方法及び溶解性分光測定装置 |
JP2011127959A (ja) * | 2009-12-16 | 2011-06-30 | Nippon Telegr & Teleph Corp <Ntt> | 定性定量分析方法、および定性定量分析システム |
JP2011257179A (ja) * | 2010-06-07 | 2011-12-22 | Nippon Telegr & Teleph Corp <Ntt> | 結晶形モニタリング方法及び結晶形モニタリング装置 |
CN103115893A (zh) * | 2013-01-30 | 2013-05-22 | 大连理工大学 | 一种检测托卡马克钨第一壁灰尘沉积层成分及厚度的装置 |
JPWO2018110481A1 (ja) * | 2016-12-15 | 2019-12-19 | フェムトディプロイメンツ株式会社 | テラヘルツ波信号解析装置、テラヘルツ波信号解析方法およびテラヘルツ波信号解析用プログラム |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10309845A1 (de) * | 2003-03-06 | 2004-09-16 | Albert-Ludwigs-Universität Freiburg | Verfahren und Vorrichtung zum berührungsfreien Identifizieren von chemischen Substanzen |
GB2402471B (en) * | 2003-06-02 | 2006-01-18 | Teraview Ltd | An analysis method and apparatus |
GB2405200B (en) * | 2003-08-22 | 2005-09-07 | Teraview Ltd | A method and apparatus for investigating a sample |
GB2405466B (en) | 2003-08-27 | 2006-01-25 | Teraview Ltd | Method and apparatus for investigating a non-planner sample |
JP4209765B2 (ja) * | 2003-12-26 | 2009-01-14 | 潤一 西澤 | テラヘルツ波画像装置 |
JP4209766B2 (ja) * | 2003-12-26 | 2009-01-14 | 潤一 西澤 | テラヘルツ電磁波反射測定装置 |
JP5166024B2 (ja) | 2004-05-26 | 2013-03-21 | ピコメトリクス、エルエルシー | 荷物及び人を検査するための反射及び透過モードのテラヘルツ画像化 |
JP4317919B2 (ja) * | 2004-05-31 | 2009-08-19 | 株式会社ニコン | 結晶の特性評価用資料の作成方法 |
TWI428271B (zh) * | 2004-06-09 | 2014-03-01 | Smithkline Beecham Corp | 生產藥物之裝置及方法 |
WO2007071092A1 (en) * | 2005-12-21 | 2007-06-28 | Etech Ag | Blood glucose sensor based on reflection or transmission spectroscopy at frequencies in the terahertz region and above the terahertz region |
GB2446166B (en) * | 2007-01-29 | 2010-05-12 | Teraview Ltd | A pharmaceutical analysis method and apparatus |
JP5422089B2 (ja) * | 2007-09-25 | 2014-02-19 | アークレイ株式会社 | 分光測定用ペレット、その製造方法および分光測定方法 |
US7795582B2 (en) * | 2007-10-19 | 2010-09-14 | Honeywell International Inc. | System and method of monitoring with temperature stabilization |
JP5328319B2 (ja) * | 2008-01-29 | 2013-10-30 | キヤノン株式会社 | テラヘルツ波を用いた検査装置及び検査方法 |
US8604433B2 (en) | 2008-05-19 | 2013-12-10 | Emcore Corporation | Terahertz frequency domain spectrometer with frequency shifting of source laser beam |
US9029775B2 (en) | 2008-05-19 | 2015-05-12 | Joseph R. Demers | Terahertz frequency domain spectrometer with phase modulation of source laser beam |
US8113427B2 (en) * | 2008-12-18 | 2012-02-14 | Ncr Corporation | Methods and apparatus for automated product identification in point of sale applications |
US9086487B2 (en) * | 2011-03-17 | 2015-07-21 | Uchicago Argonne, Llc | Radar detection of radiation-induced ionization in air |
US9103715B1 (en) | 2013-03-15 | 2015-08-11 | Joseph R. Demers | Terahertz spectrometer phase modulator control using second harmonic nulling |
US9400214B1 (en) | 2013-03-15 | 2016-07-26 | Joseph R. Demers | Terahertz frequency domain spectrometer with a single photoconductive element for terahertz signal generation and detection |
US9086374B1 (en) | 2014-04-25 | 2015-07-21 | Joseph R. Demers | Terahertz spectrometer with phase modulation and method |
US9404853B1 (en) | 2014-04-25 | 2016-08-02 | Joseph R. Demers | Terahertz spectrometer with phase modulation |
US9239264B1 (en) | 2014-09-18 | 2016-01-19 | Joseph R. Demers | Transceiver method and apparatus having phase modulation and common mode phase drift rejection |
US9429473B2 (en) | 2014-10-16 | 2016-08-30 | Joseph R. Demers | Terahertz spectrometer and method for reducing photomixing interference pattern |
CN104964932B (zh) * | 2015-06-18 | 2017-12-01 | 东莞理工学院 | 一种测量太赫兹垂直透射谱和反射谱的一体化系统及应用 |
CN108318420A (zh) * | 2017-12-22 | 2018-07-24 | 北京航天计量测试技术研究所 | 一种用于高精度气体折射率测量的光路结构 |
US11513004B2 (en) | 2019-08-08 | 2022-11-29 | Apple Inc. | Terahertz spectroscopy and imaging in dynamic environments |
US11555792B2 (en) * | 2019-08-08 | 2023-01-17 | Apple Inc. | Terahertz spectroscopy and imaging in dynamic environments with performance enhancements using ambient sensors |
TWI781456B (zh) * | 2020-10-07 | 2022-10-21 | 筑波醫電股份有限公司 | 固體劑型藥物成分檢測裝置及固體劑型藥物成分檢測方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001006915A1 (en) * | 1999-07-23 | 2001-02-01 | Teraview Limited | A radiation probe and detecting tooth decay |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US29436A (en) * | 1860-07-31 | Improvement in cigars | ||
US2792548A (en) * | 1945-05-28 | 1957-05-14 | Rca Corp | Systems and methods of gas analysis |
US3932180A (en) * | 1973-06-04 | 1976-01-13 | Xerox Corporation | Direct alpha to X phase conversion of metal-free phthalocyanine |
US4320118A (en) * | 1980-12-22 | 1982-03-16 | Syntex (U.S.A.) Inc. | Deca-, undeca-, dodeca- and tridecapeptides with thymic activity |
US5507173A (en) * | 1994-06-30 | 1996-04-16 | Shearer; Robert M. | Gas analyzer utilizing cancellation of parallel microwave beams |
US5710430A (en) * | 1995-02-15 | 1998-01-20 | Lucent Technologies Inc. | Method and apparatus for terahertz imaging |
US5789750A (en) * | 1996-09-09 | 1998-08-04 | Lucent Technologies Inc. | Optical system employing terahertz radiation |
US5939721A (en) * | 1996-11-06 | 1999-08-17 | Lucent Technologies Inc. | Systems and methods for processing and analyzing terahertz waveforms |
GB9904166D0 (en) | 1999-02-23 | 1999-04-14 | Toshiba Res Europ Ltd | Radiation imaging |
US6828558B1 (en) | 1999-06-04 | 2004-12-07 | Teraview Limited | Three dimensional imaging |
WO2001048457A1 (en) * | 1999-12-28 | 2001-07-05 | Picometrix, Inc. | System and method for monitoring changes in state of matter with terahertz radiation |
GB2372929B (en) * | 2000-03-03 | 2003-03-12 | Tera View Ltd | Apparatus and method for investigating a sample |
JP4476462B2 (ja) | 2000-03-27 | 2010-06-09 | 株式会社栃木ニコン | 半導体の電気特性評価装置 |
GB2360842B (en) * | 2000-03-31 | 2002-06-26 | Toshiba Res Europ Ltd | An apparatus and method for investigating a sample |
GB0008232D0 (en) * | 2000-04-05 | 2000-05-24 | Maintenanceinfo Com Limited | Improvements in or relating to web pages |
JP2004500582A (ja) * | 2000-04-06 | 2004-01-08 | レンセレイアー ポリテクニック インスティテュート | テラヘルツトランシーバーならびにこのようなトランシーバーを用いるテラヘルツパルスの放出および検出のための方法 |
WO2003033462A2 (en) * | 2001-10-15 | 2003-04-24 | The Regents Of The University Of Michigan | Systems and methods for the generation of crystalline polymorphs |
-
2002
- 2002-02-15 GB GB0203698A patent/GB2385415B/en not_active Expired - Fee Related
-
2003
- 2003-02-14 WO PCT/GB2003/000660 patent/WO2003069318A2/en active Application Filing
- 2003-02-14 AU AU2003207316A patent/AU2003207316A1/en not_active Abandoned
- 2003-02-14 EP EP03704788A patent/EP1474675A2/en not_active Withdrawn
- 2003-02-14 JP JP2003568389A patent/JP2005517925A/ja active Pending
- 2003-02-14 US US10/504,719 patent/US7244934B2/en not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001006915A1 (en) * | 1999-07-23 | 2001-02-01 | Teraview Limited | A radiation probe and detecting tooth decay |
Non-Patent Citations (4)
Title |
---|
JPN6008062680, D.R.Beckett, 他, ""THE FAR−INFRA−RED SPECTRA OF CRYSTALLINE ISOTACTIC POLYPROPYLENE POLYMORPHS"", European Polymer Journal, 1985, Vol.21, No.10, pp.849−852 * |
JPN6008062682, H.R. Zelsmann, 他, ""Far−infrared spectra of benzoic acid"", CHEMICAL PHYSICS LETTERS, 19911122, Vol.186, No.6, pp.501−508 * |
JPN6008062684, J. Sciesinski, 他, ""Scanning mode of the upgraded FTS−14 Digilab spectrometer − study of 8*OCB polymorphism"", Journal of Molecular Structure, 200109, Vol.596, Issues 1−3, pp.229−234 * |
JPN6008062686, A.G. Markelz, 他, ""Pulsed terahertz spectroscopy of DNA, bovine serum albumin and collagen between 0.1 and 2.0 THz"", CHEMICAL PHYSICS LETTERS, 20000331, Vol.320, pp.42−48 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008083020A (ja) * | 2006-03-17 | 2008-04-10 | Institute Of Physical & Chemical Research | 分析方法及び分析装置 |
US7977116B2 (en) | 2006-03-17 | 2011-07-12 | Canon Kabushiki Kaisha | Analysis method and analysis apparatus |
WO2008129959A1 (ja) * | 2007-04-13 | 2008-10-30 | Arkray, Inc. | 分光測定用ペレット、このペレットの製造方法及びこのペレットを用いた分光測定方法 |
JP5325097B2 (ja) * | 2007-04-13 | 2013-10-23 | アークレイ株式会社 | 分光測定用ペレット及びこのペレットを用いた分光測定方法 |
JP2010249564A (ja) * | 2009-04-13 | 2010-11-04 | Nippon Telegr & Teleph Corp <Ntt> | 溶解性分光測定方法及び溶解性分光測定装置 |
JP2011127959A (ja) * | 2009-12-16 | 2011-06-30 | Nippon Telegr & Teleph Corp <Ntt> | 定性定量分析方法、および定性定量分析システム |
JP2011257179A (ja) * | 2010-06-07 | 2011-12-22 | Nippon Telegr & Teleph Corp <Ntt> | 結晶形モニタリング方法及び結晶形モニタリング装置 |
CN103115893A (zh) * | 2013-01-30 | 2013-05-22 | 大连理工大学 | 一种检测托卡马克钨第一壁灰尘沉积层成分及厚度的装置 |
JPWO2018110481A1 (ja) * | 2016-12-15 | 2019-12-19 | フェムトディプロイメンツ株式会社 | テラヘルツ波信号解析装置、テラヘルツ波信号解析方法およびテラヘルツ波信号解析用プログラム |
Also Published As
Publication number | Publication date |
---|---|
US7244934B2 (en) | 2007-07-17 |
GB2385415B (en) | 2005-09-14 |
AU2003207316A1 (en) | 2003-09-04 |
WO2003069318A3 (en) | 2003-11-27 |
WO2003069318A2 (en) | 2003-08-21 |
GB2385415A (en) | 2003-08-20 |
GB0203698D0 (en) | 2002-04-03 |
US20050156120A1 (en) | 2005-07-21 |
EP1474675A2 (en) | 2004-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2005517925A (ja) | 分析装置及び方法 | |
US7663107B2 (en) | Method and apparatus for quantitative analysis using terahertz radiation | |
Nishizawa et al. | Spectral measurement of terahertz vibrations of biomolecules using a GaP terahertz-wave generator with automatic scanning control | |
US8456629B2 (en) | Apparatus and method for multiple-pulse impulsive stimulated raman spectroscopy | |
AU780087B2 (en) | An apparatus and method for investigating a sample | |
Svensson et al. | VCSEL-based oxygen spectroscopy for structural analysis of pharmaceutical solids | |
US20090206263A1 (en) | Terahertz time domain and frequency domain spectroscopy | |
JP6008299B2 (ja) | 光干渉計、情報取得装置、及び情報取得方法 | |
US8194246B2 (en) | Photoacoustic microcantilevers | |
WO2006092874A1 (ja) | 高分解・高速テラヘルツ分光計測装置 | |
US10451546B2 (en) | Devices and methods for coherent detection using chirped laser pulses | |
Liu et al. | Standoff reflection–absorption spectra of surface adsorbed explosives measured with pulsed quantum cascade lasers | |
JP2013536422A (ja) | 時間領域分光法における測定精度を向上させるための連続リファレンス | |
Giubileo et al. | Identification of standard explosive traces by infrared laser spectroscopy: PCA on LPAS data | |
WO2007054751A1 (en) | Method and apparatus for the selective photoacoustic detection of contaminants in a gaseous sample by making use of spectrally distant exciting wavelengths | |
US10473694B2 (en) | Optical source in microwave impedance microscopy | |
JP4601516B2 (ja) | テラヘルツ分光装置 | |
Patel et al. | A review on photoacoustic spectroscopy | |
Rey et al. | Simultaneous dual-frequency excitation of a resonant photoacoustic cell | |
Gotter et al. | Determination of drug content in semisolid formulations by non-invasive spectroscopic methods: FTIR–ATR,–PAS,–Raman and PDS | |
JP4671514B2 (ja) | 時間分解電子スピン共鳴測定方法及び装置 | |
Levitt et al. | Terahertz micro-spectroscopy using a transient mirror technique | |
CN112229814A (zh) | 太赫兹光谱测量装置、测量方法及其用途 | |
Cho et al. | Time-resolved THz phonon spectroscopy in semiconductors | |
Houde et al. | Improved detection sensitivity of D-mannitol crystalline phase content using differential spectral phase shift terahertz spectroscopy measurements |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060207 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081209 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090309 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090316 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090609 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090825 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091225 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20100223 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20100319 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101018 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101021 |